BRAF and melanoma: According to the current ASCO, ESMO, and NCCN guidelines, patients with advanced melanoma with BRAF-wildtype should either receive a dual therapy with ipilimumab plus nivolumab (see below) or a monotherapy with nivolumab or pembrolizumab.